| |
| |
|
| Insider
Information: |
Hanover Marc Steven |
| Relationship: |
Chief Executive Office... |
| City: |
Memphis |
| State: |
TN |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
124,362 |
|
|
Indirect Shares
|
47,687 |
|
|
| Direct
Value |
$42,606 |
|
|
|
Indirect Value
|
$16,338 |
|
|
| Total
Shares |
172,049 |
|
|
| Total
Value |
$58,944 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Oncternal Therapeutics Inc |
ONCT |
Chief Executive Office... |
2018-01-05 |
124,362 |
2018-01-05 |
47,687 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2018-01-05 |
4 |
S |
$11.13 |
$82,845 |
D/D |
(7,309) |
124,362 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2018-01-01 |
4 |
D |
$12.71 |
$81,306 |
D/D |
(6,397) |
131,671 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2016-10-14 |
4 |
A |
$0.81 |
$99,999 |
D/D |
123,456 |
1,380,680 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2016-01-26 |
4 |
B |
$0.65 |
$2,600 |
D/D |
4,000 |
1,257,224 |
2.73 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2016-01-25 |
4 |
B |
$0.63 |
$8,067 |
D/D |
12,813 |
1,253,224 |
2.81 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2016-01-19 |
4 |
B |
$0.50 |
$12,428 |
D/D |
25,000 |
1,240,411 |
2.81 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2016-01-15 |
4 |
B |
$0.49 |
$10,889 |
D/D |
22,100 |
1,215,411 |
2.81 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2016-01-14 |
4 |
B |
$0.47 |
$1,377 |
D/D |
2,900 |
1,193,311 |
2.73 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Chief Executive Officer |
• • – |
2015-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
750,000 |
1,190,411 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Interim CEO, President and COO |
• • – |
2014-11-14 |
4 |
A |
$0.00 |
$0 |
D/D |
227,273 |
440,411 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Interim CEO, President and COO |
• • – |
2014-09-23 |
4 |
B |
$0.75 |
$3,750 |
D/D |
5,000 |
213,138 |
2.73 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Interim CEO, President and COO |
• • – |
2014-09-17 |
4 |
B |
$0.74 |
$7,432 |
D/D |
10,000 |
208,138 |
2.81 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Interim CEO, President and COO |
• • – |
2014-08-21 |
4 |
B |
$1.00 |
$10,000 |
D/D |
10,000 |
198,138 |
2.81 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Interim CEO, President and COO |
• • – |
2014-08-20 |
4 |
B |
$1.00 |
$10,000 |
D/D |
10,000 |
188,138 |
2.81 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Interim CEO, President and COO |
• • – |
2014-08-19 |
4 |
B |
$1.01 |
$8,448 |
D/D |
8,348 |
178,138 |
2.81 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Interim CEO, President and COO |
• • – |
2014-08-15 |
4 |
B |
$1.00 |
$1,652 |
D/D |
1,652 |
169,790 |
2.73 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Interim CEO, President and COO |
• • – |
2014-08-08 |
4 |
B |
$0.95 |
$9,532 |
D/D |
10,000 |
168,138 |
2.81 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Interim CEO, President and COO |
• • – |
2014-08-07 |
4 |
B |
$0.92 |
$18,348 |
D/D |
20,000 |
158,138 |
2.81 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Interim CEO, President and COO |
• • – |
2014-08-07 |
4 |
B |
$0.92 |
$27,606 |
D/D |
30,000 |
138,138 |
2.81 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
President and COO |
• • – |
2009-02-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(250,000) |
352,875 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
President and COO |
• • – |
2009-01-29 |
4 |
B |
$10.75 |
$10,747 |
D/D |
1,000 |
108,138 |
2.81 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
President and COO |
• • – |
2009-01-27 |
4 |
B |
$10.54 |
$21,080 |
D/D |
2,000 |
107,138 |
2.81 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
President and COO |
• • – |
2007-12-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(217,027) |
602,875 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
President and COO |
• • – |
2007-03-14 |
4 |
S |
$22.10 |
$5,054,270 |
D/D |
(228,700) |
105,138 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
President and COO |
• • – |
2006-11-07 |
5 |
GD |
$0.00 |
$0 |
I/I |
18,784 |
0 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
